Cite
Langdon S, Hughes A, Taylor MA, et al. Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity. Oncoimmunology. 2018;7(8):e1458810doi: 10.1080/2162402X.2018.1458810.
Langdon, S., Hughes, A., Taylor, M. A., Kuczynski, E. A., Mele, D. A., Delpuech, O., Jarvis, L., Staniszewska, A., Cosulich, S., Carnevalli, L. S., & Sinclair, C. (2018). Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity. Oncoimmunology, 7(8), e1458810. https://doi.org/10.1080/2162402X.2018.1458810
Langdon, Sophie, et al. "Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity." Oncoimmunology vol. 7,8 (2018): e1458810. doi: https://doi.org/10.1080/2162402X.2018.1458810
Langdon S, Hughes A, Taylor MA, Kuczynski EA, Mele DA, Delpuech O, Jarvis L, Staniszewska A, Cosulich S, Carnevalli LS, Sinclair C. Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity. Oncoimmunology. 2018 May 07;7(8):e1458810. doi: 10.1080/2162402X.2018.1458810. eCollection 2018. PMID: 30221055; PMCID: PMC6136876.
Copy
Download .nbib